Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data
- 30 September 2010
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 104 (9), 1381-1385
- https://doi.org/10.1016/j.rmed.2010.06.001
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma AG
This publication has 10 references indexed in Scilit:
- Omalizumab in patients with severe persistent allergic asthma in a real-life setting in GermanyRespiratory Medicine, 2009
- Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in FranceRespiratory Medicine, 2008
- Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysisCurrent Medical Research and Opinion, 2007
- Uncontrolled asthma: A review of the prevalence, disease burden and options for treatmentRespiratory Medicine, 2006
- Population‐based assessment of adverse events associated with long‐term glucocorticoid useArthritis Care & Research, 2006
- Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseasesEuropean Journal of Pharmacology, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyThe New England Journal of Medicine, 1999